Help us: Donate
Follow us on:
×

Menu

Back

Oncotarget: MEK is a promising target in the basal subtype of bladder cancer

Oncotarget: MEK is a promising target in the basal subtype of bladder cancer

IMAGE: MEK inhibitor response correlates with basal subtype. Average and standard deviation for DSS3 response to (A) Trametinib, (B) TAK-733, (C) Normalized MEK inhibitors, and (D) Average drug response, grouped by… view more 

Credit: Correspondence to – Matthew B. Soellner – [email protected] and Sofia D. Merajver – [email protected]

Oncotarget recently published in “MEK is a promising target in the basal subtype of bladder cancer” by Merrill, et al. which reported that while many resources exist for the drug screening of bladder cancer cell lines in 2D culture, it is widely recognized that screening in 3D culture is more representative of in vivo response.

To address the need for 3D drug screening of bladder cancer cell lines, the authors screened 17 bladder cancer cell lines using a library of 652 investigational small-molecules and 3 clinically relevant drug combinations in 3D cell culture.

Their goal was to identify compounds and classes of compounds with efficacy in bladder cancer.

Utilizing established genomic and transcriptomic data for these bladder cancer cell lines, they correlated the genomic molecular parameters with drug response, to identify potentially novel groups of tumors that are vulnerable to specific drugs or classes of drugs.

Importantly, the Oncotarget authors demonstrate

read more...


Article originally posted at

www.eurekalert.org



Click here for the full story


Category
Tags